Correction: Arzerra in first line setting
This article was originally published in Scrip
Executive Summary
On 4 August 2014 we published a story about GlaxoSmithKline/Genmab's Arzerra, in which we wrongly stated that the drug did not have a first-line indication in chronic lymphocytic leukemia (CLL). In fact, Arzerra (ofatumumab) is approved in the US for use in combination with chlorambucil for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate. In the EU, ofatumumab is approved for use in combination with chlorambucil or bendamustine for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy. Ofatumumab is also approved for first-line use in Russia. The full corrected story can be found here. We apologise for the error.